NautaDutilh assisted Pharvaris B.V. with its $80 million Series C financing round, bringing its total venture funding to over $160 million to date. NautaDutilh also assisted Pharvaris with its Series B financing in 2019.
Pharvaris is a clinical-stage company focused on bringing oral bradykinin B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications.
Viking Global Investors and General Atlantic co-led the financing, with participation by Cormorant Asset Management. Current investors Foresite Capital, Bain Capital Life Sciences, venBio Partners and Venrock Healthcare Capital Partners also participated in the round.